CG Oncology (CGON) Net Income towards Common Stockholders (2023 - 2026)

CG Oncology's Net Income towards Common Stockholders history runs 4 years deep, the most recent figure standing at -$443.0 million for Q1 2026.

• Quarterly Net Income towards Common Stockholders fell 263.8% year-over-year to -$443.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$867.1 million (down 349.55% YoY) and the FY2025 annual result came in at -$161.0 million, down 82.87% from the prior year.
• Net Income towards Common Stockholders was -$443.0 million for Q1 2026 at CG Oncology, down from -$41.5 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at -$12.4 million in Q1 2023 and bottomed at -$443.0 million in Q1 2026.
• A 4-year average of -$88.1 million and a median of -$22.5 million in 2023 frame the typical range for Net Income towards Common Stockholders.
• Annual changes were most pronounced in 2024 — Net Income towards Common Stockholders slipped 16.51% — and 2025, when it tumbled 1048.9%.
• CG Oncology's Net Income towards Common Stockholders stood at -$22.5 million in 2023, then slumped by 41.39% to -$31.8 million in 2024, then plunged by 30.39% to -$41.5 million in 2025, then plunged by 968.46% to -$443.0 million in 2026.
• Business Quant data shows CGON's Net Income towards Common Stockholders at -$443.0 million in Q1 2026, -$41.5 million in Q4 2025, and -$234.4 million in Q3 2025.